Locate Bio obtains multiple late stage orthobiologics assets from RCSI

By Nikita Chaurasia  Date: 2020-09-23

Locate Bio obtains multiple late stage orthobiologics assets from RCSI

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences.

Sources state that the technologies created by the RCSI Tissue Engineering Research Group have wide human and pre-clinical data which efficaciously demonstrates their effectiveness in the treatment of both, soft and hard, tissues. The RCSI licensing transaction comprises natural collagen-based, best in class, and proprietary delivery technologies, that have been developed into numerous products for the regeneration of cartilage tissues, regeneration of bone, and the treatment of infections.

According to John von Benecke, the CEO of Locate Bio, the company is thrilled by the addition of these late stage, high-quality, and complementary products to its portfolio. He has further stated that this is a significant step in the company’s drive towards the development of a world leading orthobiologics enterprise, with its key platforms now covering numerous key areas across the clinical use waterfront.

Locate Bio continues to make excellent advancement toward spinal fusion with its lead product and eagerly looks ahead towards bringing these new assets via the process of regulatory approval in the forthcoming years, added Benecke.

Reliable sources state that Locate’s in-licencing of the assets from RCSI delivers additional breadth and depth to its existing orthobiologics portfolio, further accelerating its route to market. The company is reportedly in search of additional in-licencing or complementary acquisition opportunities that would widen its portfolio of giving surgeons the choice of best-in-class products and technologies that address the existing challenges of present products, also meeting the specific patient clinical requirement.

Ian Wilding, the Chairman at Locate Bio, has stated that the acquisition of these late stage orthobiologics assets progresses Locate’s aspirations and is another significant step in the company’s strategy towards the development of a complementary and differentiated portfolio of innovative products, with high value, strong IP, and a well-state path to market.

 

Source Credits:

https://www.locatebio.com/locate-bio-acquires-complementary-late-stage-orthobiologics-assets/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

CI NMF, Amp Energy India to jointly invest USD 200 Mn in renewables

CI NMF, Amp Energy India to jointly invest USD 200 Mn in renewables

By Nikita Chaurasia

Copenhagen Infrastructure Partners, one of the biggest renewable energy-centered fund managers worldwide, has signed an agreement with Amp Energy India Pvt Ltd. for joint equity investments of USD 200 million in renewables, using its Copenhagen Infra...

CDC updates guidelines, calls for vaccinated people to mask up

CDC updates guidelines, calls for vaccinated people to mask up

By Nikita Chaurasia

The Centers for Disease Control and Prevention issued new guidelines suggesting that people who are vaccinated against Covid-19 wear masks in public as well as indoor areas where the rate of the disease is high. The CDC also stated that teachers, sta...

iPhone’s hot streak could be hampered by global chip shortage crisis

iPhone’s hot streak could be hampered by global chip shortage crisis

By Nikita Chaurasia

Apple Inc. recently stated that the global chip shortage that has affected the sales of Macs and iPads, will now hit iPhone production and the expected revenue growth is likely to decelerate. This has resulted in lowering Apple’s shares. The c...

EV maker Rivian bags USD 2.5 Bn in a funding round led by Amazon, Ford

EV maker Rivian bags USD 2.5 Bn in a funding round led by Amazon, Ford

By Nikita Chaurasia

American electric vehicle maker Rivian Automotive LLC reportedly secured USD 2.5 billion in a funding round led by Amazon.com Inc, T. Rowe Price, D1 Capital Partners, and Ford Motor Co. In addition, the event also saw participation from Fidelity Man...

ICEA forms committee chaired by HP India MD to boost IT hardware sector

ICEA forms committee chaired by HP India MD to boost IT hardware sector

By Nikita Chaurasia

The India Cellular & Electronics Association (ICEA) recently announced the formation of a committee to promote manufacturing and exports of the IT hardware sector. The panel headed by Ketan Patel, HP India’s Managing Director, will set up a...